Component

Mouse rebaudioside-D hepatic lipid accumulation

Context-specific entity; species, compartment and exposure are stated on each claim.

1 recorded relationships. Experimental role, claim status and evidence remain attached to each record.

How nutrients influence it

Every nutrient with a recorded effect on this component, credited to the nutrient that acted rather than the chapter that recorded it. Open a nutrient to see the findings and the conditions they were measured under.

How nutrients reach it in more than one step

Chains of two or more recorded steps that end here, grouped by the nutrient they start from. Each step is a separate finding, so a chain is a route a mechanism could take, not proof that it does.

Tracing routes…

What it does

Every recorded relationship this component is part of, grouped by its role. Plain wording comes first; the technical statement follows.

Recorded relationships

What acts on it

  1. Rebaudioside D at 50 mg/kg orally for 12 weeks reduced hepatic triglycerides, cholesterol and lipid peroxidation in male high-fat/high-sucrose-fed mice.

    Experimental context and source evidence
    evidence_access
    Primary abstract
    experimental_model
    Male C57BL/6J diet-induced obesity; rebaudioside A and vehicle comparators.
    limitations
    Mouse dosing is not ordinary human food exposure; lower lipid content does not identify a unique molecular target.
    nutrient_topic
    Stevia collection; species, compartment, exposure, co-substrates and manipulation remain explicit. · Stevia
    plain_language
    A less common glycoside had a liver phenotype in an obesity model.
    primary_references
    Rebaudioside D decreases adiposity and hepatic lipid accumulation in a mouse model of obesity. · 2024 · https://pubmed.ncbi.nlm.nih.gov/38321177/ · DOI 10.1038/s41598-024-53587-y

    Stevia: glycoside metabolism, taste, ion channels and cross-nutrient mechanisms (2026-09-19) · lines 418–424

    AI-assisted research curation; primary references, access levels and experimental limitations individually identified. Not publisher full text. · supports · Male C57BL/6J diet-induced obesity; rebaudioside A and vehicle comparators. · source_derived_draft · unverified_draft

    ## stevia-rebd-liver A less common glycoside had a liver phenotype in an obesity model. Rebaudioside D at 50 mg/kg orally for 12 weeks reduced hepatic triglycerides, cholesterol and lipid peroxidation in male high-fat/high-sucrose-fed mice. Model: Male C57BL/6J diet-induced obesity; rebaudioside A and vehicle comparators. Limitations: Mouse dosing is not ordinary human food exposure; lower lipid content does not identify a unique molecular target. Evidence access: Primary abstract Rebaudioside D decreases adiposity and hepatic lipid accumulation in a mouse model of obesity. · 2024 · https://pubmed.ncbi.nlm.nih.gov/38321177/ · DOI 10.1038/s41598-024-53587-y
    Complete structured claim and evidence

In the sources

Preserved passages that mention this component, quoted exactly. Open one to read it in context.

    This is a research prototype built from draft material. It is not medical advice, and its statements still await verification against the original studies.

    Evidence, AI assistance and curation standards